Strategic buy and sell-side mergers, acquisitions, restructurings, sales, divestitures and/or strategic combinations
Private investments, including Private Investments in Public Equity (PIPEs), Initial Public Offerings (IPOs) and registered direct offerings (RDOs) are all options from clients who engage us for services.
Licensing and partnership arrangements provide resources for growth without equity dilution or ownership sale from existing shareholders. Such arrangements can also provide ample capital for further expansion.
Our team provides specialized capital advisory and investment banking solutions to pharmaceutical and biotechnology companies across the middle market. Our pharmaceutical team assists clients across a number of key niches including over-the-counter products and services, drug discovery and development, generic drugs, biosimilar, nutraceuticals, medical technology and agricultural biotechnology.
By providing strategic and holistic analysis and deal processing tools, we assist our clients in complete value maximization across the value chain from growth financing to mergers and acquisitions. Our expert network of experienced deal makers understands the strict regulatory hurdles involved in the manufacturing and marketing of medical pharmaceuticals. This subject matter expertise, combined with a detailed understanding of both investors and players in the field, creates a quality solution for clients looking for the right investment bank in pharmaceuticals.
Because no deal or project is exactly alike, our pharmaceutical and biotech teams tailor client engagements to match the short and long term goals of our client’s businesses.